TIGAR cooperated with glycolysis to inhibit the apoptosis of leukemia cells and associated with poor prognosis in patients with cytogenetically normal acute myeloid leukemia

Table 2 Chemotherapy regimens of AML patients

Induction	Consolidation	Case numbers	Dosage of anthracyclines (each course)
IA	Intermediate dose cytarabine	74	Idarubicin 12 mg/m²/day, IV, day 1 to 3
CAG	CAG	12	Aclarubicin 10 mg/day, IV, day 1 to 8
DCAG	DCAG	23	Aclarubicin 10 mg/day, IV, day 3 to 6

IA: idarubucin 12 mg/m² once daily intravenous (IV) from day 1 to 3 combined with cytarabine 100 mg/m² continuous intravenous (CIV) from day 1 to 7. CAG: granulocyte colony-stimulating factor (G-CSF) of 300 μg/day (day 0–14) subcutaneous injection (SQ) for priming combined with cytarabine of 10 mg/m² SQ q12h for 14 days (day 1–14), aclarubicin of 10 mg/day IV for 8 days (day 1–8). The G-CSF priming was discontinued if white blood count (WBC) was >20 × 10⁹/L. DCAG: decitabine of 15 mg/m² IV for 5 days (day 1–5) and G-CSF of 300 μg/day (day 0–9) SQ for priming combined with cytarabine of 10 mg/m² SQ q12h for 7 days (day 3–9), aclarubicin of 10 mg/day IV for 4 days (day 3–6). The G-CSF priming was discontinued if WBC was >20 × 10⁹/L

ISSN: 1756-8722